IFNB1 and multiple sclerosis: Interferon-beta was compared against methotrexate for idiopathic and multiple sclerosis-associated intermediate uveitis in a small randomized controlled clinical trial that showed superiority of interferon-beta in improving visual acuity and reducing macular edema after 3 months of treatment [33].